Outlook Therapeutics (OTLK) Cash & Equivalents (2015 - 2026)

Outlook Therapeutics (OTLK) has reported Cash & Equivalents for 12 consecutive years, with $7.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 2.54% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (up 2.54% YoY), while the FY2025 annual figure was $8.1 million, down 45.85% from the prior year.
• Cash & Equivalents fell to $7.7 million in Q1 2026 per OTLK's latest filing, from $8.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $58.4 million in Q1 2022 and bottomed at $5.7 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $23.9 million across 5 years, with a median of $17.4 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 57.19% — and 2025, when it sank 84.0%.
• Outlook Therapeutics' Cash & Equivalents stood at $52.3 million in 2022, then tumbled by 80.21% to $10.4 million in 2023, then plunged by 44.94% to $5.7 million in 2024, then soared by 52.17% to $8.7 million in 2025, then slipped by 10.71% to $7.7 million in 2026.
• Business Quant data shows OTLK's Cash & Equivalents at $7.7 million in Q1 2026, $8.7 million in Q4 2025, and $8.1 million in Q3 2025.